In adults with BMI ≥27 kg/m2 and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk

Mayer B Davidson

doi:10.7326/J23-0089

In adults with BMI ≥27 kg/m² and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk

Ann Intern Med. 2023 Nov;176(11):JC129. doi: 10.7326/J23-0089. Epub 2023 Nov 7.

Author

Mayer B Davidson¹

Affiliation

¹ Charles R. Drew University, Los Angeles, California, USA (M.B.D.).

PMID: 37931265
DOI: 10.7326/J23-0089

Abstract

Garvey WT, Frias JP, Jastreboff AM, et al; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402:613-626. 37385275.

Publication types

Comment

MeSH terms

Adult
Body Mass Index
Clinical Trials, Phase III as Topic
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Humans
Hypoglycemic Agents / therapeutic use
Life Style
Multicenter Studies as Topic
Randomized Controlled Trials as Topic
Tirzepatide
Weight Loss

Substances

Hypoglycemic Agents
Tirzepatide